Comparison of Two Different Fascial Treatments
Launched by DOĞAN BURAK ENDAMLI · Nov 28, 2024
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Chronic low back pain is a disease that causes the loss of working days in the world, causes significant disability and health costs, and cannot be fully diagnosed. It ranks second among the job loss factors and is considered the most important factor affecting the decline in production.
Until recent years, conservative treatment of all types of low back pain included bed rest for a certain period of time. This situation has changed over time with studies, and today's treatment is to gradually increase the level of activity according to the person's level with minimal bed rest.
Chronic lo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients between 35-60 years old
- • Patients with low back pain for at least 3 months
- • Patients with pain 4 and above according to VAS
- • Having not received FTR and manual therapy for the last 3 months
- • Those who have not received medical treatment for the last 3 months and those who will not
- Exclusion Criteria:
- • Those with a history of back and spine surgery
- • Patients with a history of trauma
- • Those with instable neurological findings
- • Having a pathology such as hernia and root pressure in the lumbal region
- • Regular users of analgesic and anti-inflammatory drugs
- • Communication problem that will prevent the implementation of evaluations and/or treatment program
About Doğan Burak Endamli
Doğan Burak Endamli is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient care and treatment outcomes, the organization collaborates with various stakeholders, including healthcare professionals, research institutions, and regulatory bodies. Leveraging a robust framework for conducting clinical trials, Doğan Burak Endamli emphasizes ethical standards, rigorous methodologies, and comprehensive data analysis to ensure the integrity and efficacy of its studies. Through its efforts, the sponsor aims to contribute valuable insights and breakthroughs to the medical community, ultimately improving the health and well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gaziantep, Sehitkamil, Turkey
Patients applied
Trial Officials
kezban bayramlar, profesör
Study Director
Hasan Kalyoncu University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported